Items where authors include "Nash, P."

Article

Kerschbaumer, A., Smolen, J.S., Nash, P. et al. (12 more authors) (2020) Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors : a systematic literature research. RMD Open, 6 (3). e001374.

Conference or Workshop Item

Torgutalp, M., Azevedo, V., Baraliakos, X. et al. (39 more authors) (2024) Characteristics of Patients with Psoriatic Arthritis Presenting with Axial Involvement: Results of a Prospective International Multicenter Study (AXIS). In: ACR Convergence 2024, 14-19 Nov 2024, Washington, D. C..

Tillett, W.R., Coates, L., Vis, M. et al. (7 more authors) (2023) Early Improvement in 3 Visual Analogue Scale (3VAS)/4VAS Predicts Reduced Rates of Radiographic Change in Bio-naive Active Psoriatic Arthritis Patients Receiving Guselkumab Treatment. In: ACR Convergence 2023, 10-15 Nov 2023, San Diego, CA.

Tillett, W., Coates, L., Vis, M. et al. (7 more authors) (2023) POS1535 Early improvement in 3VAS/4VAS predicts reduced rates of radiographic change in bio-naive active psoriatic arthritis patients receiving Guselkumab treatment. In: EULAR 2023 European Congress of Rheumatology, 31 May - 03 Jun 2023, Milan, Italy.

McGonagle, D., Haaland, D., Helliwell, P. orcid.org/0000-0002-4155-9105 et al. (6 more authors) (2023) Improvement in Key PsA Core Domains With Guselkumab Treatment in an Enriched Population of ACR20 Non-responders at Week 24: Post Hoc Analysis of Two Phase 3 Studies. In: ACR Convergence 2022, 10-14 Nov 2022, Philadelphia, PA.

Proceedings Paper

Tillett, W., Coates, L., Vis, M. et al. (9 more authors) (2023) P176 Minimal important difference, minimal detectable change and disease activity thresholds for two novel composite instruments, three visual analogue scale/VAS and four visual analogue scale/VAS, in patients with psoriatic arthritis: pooled analysis of three phase III studies. In: Rheumatology. British Society for Rheumatology Annual Conference 2023, 24-26 Apr 2023, Manchester, UK. Oxford University Press .

Tillett, W., Coates, L., Vis, M. et al. (9 more authors) (2022) 1017: Minimal Important Difference (MID), Minimal Detectable Change (MDC),and Disease Activity Thresholds for Two Novel Composite Instruments(3VAS, 4VAS) in Patients with Psoriatic Arthritis: Pooled Analysis of ThreePhase 3 Studies. In: Arthritis & Rheumatology. ACR Convergence 2022, 10-14 Nov 2022, Philadelphia, USA. Wiley , pp. 2013-2015.

McGonagle, D., Haaland, D., Helliwell, P. et al. (6 more authors) (2022) 2113: Improvement in Key PsA Core Domains with Guselkumab Treatment in an Enriched Population of ACR20 Non-Responders at Week 24: Post Hoc Analysis of Two Phase 3 Studies. In: Arthritis & Rheumatology. ACR Convergence 2022, 10-14 Nov 2022, Philadelphia, USA. , pp. 4182-4184.

Coates, L., Gossec, L., Contre, C. et al. (8 more authors) (2022) 2127: Guselkumab Provides Continued Improvement in Key Domains of Psoriatic Arthritis Through 2 Years. In: Arthritis & Rheumatology. ACR Convergence 2022, 10-14 Nov 2022, Philadelphia, USA. Wiley , pp. 4214-4216.

Coates, L., Gossec, L., Contre, C. et al. (8 more authors) (2022) POS1017 Guselkumab Provides Continued Improvement In Key Domains Of Psoriatic Arthritis Through 2 Years. In: Annals of the Rheumatic Diseases. EULAR 2022 European Congress of Rheumatology, 01-04 Jun 2022, Copenhagen, Denmark. BMJ , pp. 818-819.